s defined in the DSM-IV-TR (1), social anxiety disorder (SAD), or social phobia, is now well recognized as a prevalent and significantly impairing disorder with an onset early in life. Since Liebowitz and colleagues' commentary regarding the neglect of SAD in the contemporary literature (2) , there has been considerable research into the nature of SAD, its natural history, its biological and environmental underpinnings, and its treatment. There has also been concern about the pathologizing of normal temperamental variations. This concern is most commonly linked to the use of pharmacologic treatments, particularly in younger patients, and has been exacerbated by the debate about the safety of antidepressant treatment of children and adolescents (3) .
Epidemiologic studies show that SAD is among the most prevalent of all mental disorders. It is frequently comorbid with other anxiety disorders, mood disorders, and substance use disorders (4) . It also remains undiagnosed and untreated for many years after onset. Few psychiatric disorders involve a debate about whether the condition in question should be regarded as a disorder and, if so, whether people with the condition should receive treatment for their distress. In the case of SAD, the debate extends to the question of whether the therapeutic approach with the largest data base regarding efficacy-namely, psychopharmacology-should be employed.
Longitudinal investigations of children with behavioural inhibition show that many retain these temperamental and behavioural features as they develop (5) and that they have characteristics of social anxiety and avoidance. Untreated SAD does not usually remit. The educational, interpersonal and vocational pathways of subjects with social anxiety are frequently adversely affected. Early recognition and early intervention are being increasingly advocated in other disorders and deserve consideration for the child and adolescent suffering from anxiety. It has been found that few children identified as meeting criteria for SAD receive any treatment (6) . In a sample of 190 parents, only 31% of the children who suffered from current anxiety disorder had received any treatment, compared with 40% of those with depression and 79% of those with attention-deficit hyperactivity disorder. With the exception of specific phobia, the commonest anxiety disorder was social phobia, which had a 1-year prevalence rate of 3.2% (standard error 1.3%) (6) .
The approach of intervening early begs the question of where the threshold is set for defining a "case." Wakefield and colleagues (7) offer a provocative reexamination of social anxiety and its disorders, founded in a critique of the current DSM criteria. In their view, the number of true cases of SAD is markedly lower than epidemiologic studies based on DSM or ICD criteria recognize in community samples. These authors raise the concept of nondisordered social fears that cause suffering as a condition separate from what psychiatrists view as SAD.
Should we reexamine the criteria for caseness? Will DSM-V take on that task? It has always appeared unlikely that marked increases in case recognition over brief periods of time reflect significant shifts in the actual prevalence of similarly defined cases. Thus SAD's current high prevalence (often quoted as 13.5%), compared with the fact that it was virtually unrecognized 20 years ago, reflects changes in awareness, in the criteria used for diagnosis, in the methods of screening for cases, and in the thresholds used to define caseness.
If we cannot be reasonably sure of how to define cases, do we have sufficient evidence to recommend treatment? Our understanding of the efficacy of interventions in SAD is based on 2 streams of investigation: the common dichotomy of psychosocial and pharmacologic treatments, together with the combination of these treatments in willing subjects diagnosed with SAD according to DSM-III or DSM-IV criteria. Rowa and Antony provide a useful review of psychosocial interventions, including several recent developments in cognitivebehavioural approaches, and they also briefly discuss the evidence in regard to combination therapies (8) .
Several investigators have reviewed the efficacy of antidepressant treatment for SAD. Stein and colleagues reported through the Cochrane Collaboration the available information to that point (9). They reviewed 36 randomized controlled trials (RCTs) using selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase inhibitors. Twenty-six trials demonstrated that all medication groups showed short-term superiority in treatment response, compared with placebo. The SSRIs were significantly more effective than both moclobemide and, to a lesser extent, brofaramine. Long-term medication treatment was supported by the findings of 4 maintenance and 4 relapse-prevention studies. The results for performance anxiety RCTs were less clear. In addition to proving superior to no active treatment, the medications also reduced comorbid depression and disability associated with SAD.
Since Stein and others' review, evidence has accumulated about the efficacy of other SSRIs and serotonin norepinephrine reuptake inhibitors (SNRIs), including escitalopram (10, 11) , paroxetine (12, 13) , and venlafaxine (14) . In addition to its results in short-term efficacy studies, paroxetine has been shown to prevent relapse of SAD in a 24-week study.
Paroxetine was more effective than placebo in a major 16-week study of 322 children and adolescents treated with medication or placebo (12) . The response rate in the paroxetine group was 77.6%, compared with 38.3% in the placebo group. Although 47.8% of the subjects treated with active medication improved "very much," as is usual in adult investigations, 50% did not. One of the important findings was that the rate of adverse effects in both groups was low. However, the rate of suicidal ideation or threat was higher in the paroxetine group than among the control subjects (4 vs 0, P = 0.12). None of the events were considered to be serious, and none were attributed to the medication used.
Venlafaxine extended release had efficacy comparable with that of paroxetine in a 12-week investigation, in contrast to placebo (15) . Venlafaxine was significantly more effective than placebo by week 1, whereas paroxetine took until week 3 to show differential efficacy from placebo. Response rates for both active agents were approximately 60%. Fluvoxamine controlled release has also been shown to be a well-tolerated, effective method of reducing social anxiety symptoms (16) .
In addition, agents beyond the antidepressant group have been investigated as primary treatments. In an 11-week trial of adults with social phobia, pregabalin 600 mg daily was superior to placebo, whereas pregabalin 150 mg daily was not (17) . St John's wort was not found to be more effective than placebo in a study of 40 subjects over 12 weeks (18) . An open study of topiramate pointed to some suggestion of improvement over 16 weeks, but 50% of subjects dropped out before study completion; further, although 11 of 23 in the intent-to-treat sample were responders, only 6 were considered to be in remission at study end (19) .
Social anxiety can no longer claim to be a neglected area of study. However, determining who should be regarded as needing treatment; how they are to be recognized in the community; which treatment they should receive, depending on their condition's severity and their age; how treatments (particularly evidence-based psychosocial interventions) can be made accessible; and how we get beyond a 50% response rate remain significant areas for study and improvement. The issue of the safety of the most commonly available treatments-SSRIs or SNRIs-continues to be the subject of study and debate (20) . Despite all the caveats, many available and effective treatments exist that can and should be offered to people who meet the criteria for the diagnosis of SAD.
